Trial
NCT06102213
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Prolacta Bioscience
Collaborators
—
Condition
Hematologic Malignancy
Intervention
B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)
Why stopped
Sponsor business decision to terminate the study early
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-19